# Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)

> **NCT00243230** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 116 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Vicriviroc 30 mg
- **DRUG:** Vicriviroc 20 mg
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Background ART Regimen

## Key facts

- **NCT ID:** NCT00243230
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09-19
- **Primary completion:** 2007-10-19
- **Final completion:** 2011-03-17
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2021-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00243230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00243230, "Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00243230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*